BETAMETHASONE VALERATE

/static/temp/default.svg

Search structure


Trade Names	BETA-VAL BETADERM BETAMETHASONE VALERATE BETATREX DERMABET LUXIQ VALISONE VALNAC
Synonyms	Audavate Audavate rd Beta-val Betacap Betaderm Betameth val in coal tar Betamethasone (as valerate) Betamethasone 17-valerate Betamethasone valerate Betamethasoni valeras Betatrex Betesil Betnovate rd Betnovate-c Betnovate-n Bettamousse Bextasol Dermabet Fucibet Luxiq NSC-755912 Rinderon v Stanoval Tokuderm Valisone Valnac Xemacort
Status
Molecule Category	Free-form
UNII	9IFA5XM7R2
EPA CompTox	DTXSID7022673
Parent Compound:	BETAMETHASONE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SNHRLVCMMWUAJD-SUYDQAKGSA-N
Smiles	CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI	InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C27H37FO6
Molecular Weight	476.59
AlogP	3.64
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	100.9
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	34.0

Bioactivity

Mechanism of Action	Action	Reference
Glucocorticoid receptor agonist	AGONIST	PubMed Wikipedia


Protein: Glucocorticoid receptor Description: Glucocorticoid receptor Organism : Homo sapiens P04150 ENSG00000113580

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	-	-	-	67
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	10

Assay Description	Organism	Bioactivity	Reference
Inhibition of ear swelling induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in murine chronic irritative contact dermatitis model at 0.001 mg/ear (in vivo)	Mus musculus	41.0 %
Inhibition of ear weight induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in murine chronic irritative contact dermatitis model at 0.001 mg/ear (in vivo)	Mus musculus	38.0 %
Inhibition of myeloperoxidase (MPO) activity induced by TPA in murine chronic irritative contact dermatitis model at 0.001 mg/ear (in vivo)	None	67.0 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	38.6 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	10.24 %
Antiinflammatory activity in topical allergic contact dermatitis mouse model assessed as inhibition of TNFalpha in tissue at 0.003 mg administered topically	Mus musculus	75.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	15.28 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	2.908 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.09 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.09 %

Cross References

Resources	Reference
ChEBI	31277
ChEMBL	CHEMBL1497
DrugCentral	354
FDA SRS	9IFA5XM7R2
PubChem	16533
SureChEMBL	SCHEMBL7270
ZINC	ZINC000003882052

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).